NCT04312672View on ClinicalTrials.gov

Long-term Follow-up Gene Therapy Study for RPGR- XLRP

Active, not recruitingOBSERVATIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

November 18, 2026

Study Completion Date

November 18, 2026

Conditions
X-Linked Retinitis Pigmentosa
Interventions
BIOLOGICAL

AAV5-hRKp.RPGR

Participants will not receive any intervention in this study. Participants from the retrospective (MGT009-NCT03252847) study will be follow-up.

Trial Locations (5)

15213

University of Pittsburgh Medical Center, Pittsburgh

48105

Univ of Michigan Medical Center, Ann Arbor

02114

Massachusetts Eye and Ear Infirmary, Boston

LS9 7TF

Leeds Teaching Hospitals NHS Trust, Leeds

EC1V 9EL

Moorfields Eye Hospital, London

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04312672 - Long-term Follow-up Gene Therapy Study for RPGR- XLRP | Biotech Hunter | Biotech Hunter